{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=13&q=hormone-sensitive", "query": { "q": "hormone-sensitive", "condition": "Prostate Cancer", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 159, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=14&q=hormone-sensitive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=12&q=hormone-sensitive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:35:20.386Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06244004", "title": "FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytotoxic Chemotherapy", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 125, "start_date": "2024-02-18", "completion_date": "2028-02-18", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 6, "location_summary": "Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "DeKalb", "state": "Illinois" }, { "city": "Geneva", "state": "Illinois" }, { "city": "Oak Brook", "state": "Illinois" }, { "city": "Orland Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244004" }, { "nct_id": "NCT03860987", "title": "Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castrate Sensitive Prostate Cancer" ], "interventions": [ { "name": "goserelin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "18F-DCFPyL", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 12, "start_date": "2019-04-30", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860987" }, { "nct_id": "NCT02020070", "title": "Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Sensitive Prostate Cancer" ], "interventions": [ { "name": "Degarelix", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2013-12-18", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020070" }, { "nct_id": "NCT02278185", "title": "Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage III Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "histrelin acetate", "type": "DRUG" }, { "name": "triptorelin", "type": "DRUG" }, { "name": "degarelix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2015-11-11", "completion_date": "2024-07-18", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 2, "location_summary": "Aurora, Colorado • Fort Collins, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02278185" }, { "nct_id": "NCT07711002", "title": "Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1330, "start_date": "2026-09-15", "completion_date": "2033-05-27", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 42, "location_summary": "Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07711002" }, { "nct_id": "NCT06660862", "title": "Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Darolutamide", "type": "DRUG" }, { "name": "Physician choice Androgen Deprivation (Hormone) Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 80, "start_date": "2026-11", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06660862" }, { "nct_id": "NCT02097303", "title": "Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carolina Research Professionals, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2014-03", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-02-01", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 5, "location_summary": "Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more", "locations": [ { "city": "Towson", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" }, { "city": "Springfield", "state": "Oregon" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02097303" }, { "nct_id": "NCT04644770", "title": "A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms", "Adenocarcinoma" ], "interventions": [ { "name": "JNJ-69086420", "type": "DRUG" }, { "name": "JNJ-78278343", "type": "DRUG" }, { "name": "Stereotactic body radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 144, "start_date": "2020-11-12", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644770" }, { "nct_id": "NCT07140900", "title": "Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Xaluritamig", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2025-10-07", "completion_date": "2030-03-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 8, "location_summary": "San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07140900" }, { "nct_id": "NCT02730338", "title": "INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "High intensity aerobic and resistance training", "type": "BEHAVIORAL" }, { "name": "Psychosocial support", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Movember Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 866, "start_date": "2016-01", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-15T18:35:20.386Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02730338" } ] }